Literature DB >> 6110271

Experimental non-A, non-B hepatitis: four types of cytoplasmic alteration in hepatocytes of infected chimpanzees.

U Pfeifer, R Thomssen, K Legler, U Böttcher, W Gerlich, E Weinmann, O Klinge.   

Abstract

On the occasion of an outbreak of non-A, non-B hepatitis in a plasmapheresis centre (81 cases, incubation period: 3--6 weeks) a pool of 12 plasma samples was obtained in the early phase of increasing transaminases. Two chimpanzees were inoculated, each receiving 12 ml of the pooled plasma. After an incubation period of 10--12 weeks a mild non-A, non-B hepatitis developed. Serum transaminases were slightly elevated. Needle biopsies, taken fortnightly, showed a slight activation of Kupffer cells (6--8 weeks), single cell necroses, and infiltration of the portal tracts (10--13 weeks). Electron microscopically four types of cytoplasmic change, were found in hepatocytes and assumed to be specific for the infection, Type I: Sponge-like inclusion (6 weeks after inoculation) composed of a dense matrix and irregularly arranged membranes. Type II: Attaching curved membranes (8 weeks), developing by close apposition of two cisternae of smooth endoplasmic reticulum. Type III: Cylindrical complexes (10 weeks), already described in literature. Type IV: Microtubular aggregates, usually neighbouring type III structures. The findings suggest 1) that the agent of the present infection is, at least in part, identical with that of the long incubation type of experimental non-A, non-B hepatitis, and 2) that ultrastructural alterations may precede manifest hepatitis.

Entities:  

Mesh:

Year:  1980        PMID: 6110271     DOI: 10.1007/bf02899184

Source DB:  PubMed          Journal:  Virchows Arch B Cell Pathol Incl Mol Pathol        ISSN: 0340-6075


  26 in total

1.  Organ specificity of the antigens reacting with the 48-1 and S-1 antibodies in chimpanzees infected with hepatitis C virus.

Authors:  M Sugitani; Y K Shimizu; J Azumi; T Maeda; K Abe; T Shikata
Journal:  Int J Exp Pathol       Date:  1991-10       Impact factor: 1.925

2.  Tubuloreticular structures (TRS) and cylindric confronting cisternae (CCC) in childhood dermatomyositis.

Authors:  A Fidziańska; H H Goebel
Journal:  Acta Neuropathol       Date:  1989       Impact factor: 17.088

3.  Enhanced expression of interferon-regulated genes in the liver of patients with chronic hepatitis C virus infection: detection by suppression-subtractive hybridization.

Authors:  R Patzwahl; V Meier; G Ramadori; S Mihm
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

4.  Palmitoylation and polymerization of hepatitis C virus NS4B protein.

Authors:  Guann-Yi Yu; Ki-Jeong Lee; Lu Gao; Michael M C Lai
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

5.  Tubuloreticular structures in laryngeal carcinoma.

Authors:  P Schenk
Journal:  Arch Otorhinolaryngol       Date:  1984

6.  Density heterogeneities of hepatitis C virus in human sera due to the binding of beta-lipoproteins and immunoglobulins.

Authors:  R Thomssen; S Bonk; A Thiele
Journal:  Med Microbiol Immunol       Date:  1993-12       Impact factor: 3.402

7.  Human ezrin-moesin-radixin proteins modulate hepatitis C virus infection.

Authors:  Terence N Bukong; Karen Kodys; Gyongyi Szabo
Journal:  Hepatology       Date:  2013-09-17       Impact factor: 17.425

8.  Detection of the hepatitis C virus genome in acute and chronic experimental infection in chimpanzees.

Authors:  G G Schlauder; G J Leverenz; C W Amann; R R Lesniewski; D A Peterson
Journal:  J Clin Microbiol       Date:  1991-10       Impact factor: 5.948

9.  Renal ultrastructural markers in AIDS-associated nephropathy.

Authors:  P Chander; A Soni; A Suri; R Bhagwat; J Yoo; G Treser
Journal:  Am J Pathol       Date:  1987-03       Impact factor: 4.307

10.  Bovine viral diarrhea virus NS4B protein is an integral membrane protein associated with Golgi markers and rearranged host membranes.

Authors:  Erica Weiskircher; Jason Aligo; Gang Ning; Kouacou V Konan
Journal:  Virol J       Date:  2009-11-03       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.